Clinical Trials · NCT07284979
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Kailera
- Enrollment
- 1,270
- Start date
- Dec 2025
- Locations
- 60 sites, 5 countries
- Primary endpoint
- Percent Change From Baseline in Body Weight at Week 76